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Abstract In the hippocampal formation of Alzheimer’s
disease (AD) patients, both focal and diffuse deposits of
Ab peptides appear in a subregion- and layer-speciﬁc
manner. Recently, pyroglutamate (pGlu or pE)-modiﬁed
Ab peptides were identiﬁed as a highly pathogenic and
seeding Ab peptide species. Since the pE modiﬁcation is
catalyzed by glutaminyl cyclase (QC) this enzyme emerged
as a novel pharmacological target for AD therapy. Here, we
reveal the role of QC in the formation of different types of
hippocampal pE-Ab aggregates. First, we demonstrate that
both, focal and diffuse pE-Ab deposits are present in
deﬁned layers of the AD hippocampus. While the focal
type of pE-Ab aggregates was found to be associated with
the somata of QC-expressing interneurons, the diffuse type
was not. To address this discrepancy, the hippocampus of
amyloid precursor protein transgenic mice was analysed.
Similar to observations made in AD, focal (i.e. core-
containing) pE-Ab deposits originating from QC-positive
neurons and diffuse pE-Ab deposits not associated with QC
were detected in Tg2576 mouse hippocampus. The hip-
pocampal layers harbouring diffuse pE-Ab deposits receive
multiple afferents from QC-rich neuronal populations of
the entorhinal cortex and locus coeruleus. This might point
towards a mechanism in which pE-Ab and/or QC are being
released from projection neurons at hippocampal synapses.
Indeed, there are a number of reports demonstrating the
reduction of diffuse, but not of focal, Ab deposits in hip-
pocampus after deafferentation experiments. Moreover, we
demonstrate in neurons by live cell imaging and by enzy-
matic activity assays that QC is secreted in a constitutive
and regulated manner. Thus, it is concluded that hippo-
campal pE-Ab plaques may develop through at least two
different mechanisms: intracellularly at sites of somatic QC
activity as well as extracellularly through seeding at ter-
minal ﬁelds of QC expressing projection neurons.
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Introduction
Alzheimer’s disease (AD) is the most prevalent neurode-
generative disorder characterized by the appearance of
neuroﬁbrillary tangles, loss of speciﬁc neuronal popula-
tions and formation of Ab deposits in neocortical and
hippocampal brain structures and in vulnerable subcortical
nuclei (AD) [7, 8, 52]. Ab peptides are generated by
sequential proteolytic cleavage of the amyloid precursor
protein (APP) by b- and c-secretases [23]. A substantial
proportion of Ab peptides undergoes N-terminal truncation
by two or by ten amino acids and subsequent cyclization of
N-terminal glutamate (E) into pyroglutamate (pE), result-
ing in pE3-Ab and pE11-Ab peptides [41, 44, 45]. Such
pE-Ab peptides have been shown by biochemical and
histological methods to be major constituents of Ab
deposits in sporadic and familial AD [34, 38, 44]. Also in a
recent study using mass spectrometry, pE-Ab peptides
were identiﬁed as a signiﬁcant—although not predomi-
nant—Ab peptide species in brains from sporadic and
familialADpatients[40].Basedonanumberofindependent
biophysical, biochemical and histological observations,
pE-Ab peptides could play a prominent role in AD patho-
genesis. For example, the cyclization of glutamic acid into
a pE residue leads to a loss of N-terminal charge resulting in
acceleratedaggregationofpE-Ab[26,42]andco-aggregation
ofnon-modiﬁedAbpeptides[15,31,48,51].Furthermore,the
pE-modiﬁcation confers resistance to degradation by most
aminopeptidases as well as Ab-degrading endopeptidases
[43]. Finally, a particularly neurotoxic effect of pE-Ab
peptides on primary neurons, neuronal cell lines and neu-
rons of APP transgenic animals in vivo has been described
[1, 42, 59].
Recently, glutaminyl cyclase (QC) has been shown to be
the enzyme catalyzing pE-Ab peptide generation in cell-
free assays [47], in cell culture [13, 14] and in experimental
animals [49, 50]. Chronic inhibition of QC in transgenic
mouse and Drosophila models of AD resulted in reduced
pE-Ab peptide generation and in diminished total Ab
peptide concentrations in brain [49]. Thus, the enzymatic
activity of QC appears to be a prerequisite for pE-Ab
peptide generation and QC expression may render neurons
especially vulnerable.
In mammalian brain, signiﬁcant neuronal QC expression
in the hypothalamus has been described decades ago, and
has been shown to be involved in the maturation of peptide
hormones such as orexin A, gastrin, gonadotropin- and
thyrotropin-releasing hormones and neurotensin [6, 9, 20,
39]. Recently, we demonstrated pronounced QC immuno-
reactivity in a subpopulation of neocortical neurons and of
GABAergic interneurons in the mouse hippocampus [25].
Moreover, we observed robust QC expression in mouse and
human brain in AD-vulnerable subcortical brain regions,
such as nucleus basalis Meynert, locus coeruleus and
Edinger–Westphal nucleus [36].
However, contrary to the thorough biochemical char-
acterization of pE-Ab formation by QC, a conclusive
histological relation of QC expression and pE-Ab pathol-
ogy in vivo is still lacking. In order to address this issue, we
ﬁrst analysed the pE-Ab immunoreactivity in post mortem
hippocampal brain tissue of AD patients. The hippocampus
was chosen as model system because of its well-described
connectivity and laminated organization with segregated
cell and ﬁbre layers [21], early-onset pE-Ab plaque gen-
eration and signiﬁcant QC expression in mouse
hippocampus [25]. Here, we report for the ﬁrst time an
analysis of the spatial relation of distinct types of pE-Ab
deposits with QC immunoreactive neurons and target ﬁelds
of QC-rich projection neurons in the human hippocampal
formation. To get further insights from an animal model of
AD, we also analysed the temporal and spatial occurrence
of pE-Ab plaques in APP transgenic Tg2576 mice and
related it histologically to QC expression.
Materials and methods
Human brain tissue
Case recruitment and characterization of human brain
tissue
Case recruitment and autopsy were performed in accor-
dance with guidelines effective at Banner Sun Health
Research Institute Brain Donation Program of Sun City,
Arizona [3]. The required consent was obtained for all
cases. The deﬁnite diagnosis of AD for all cases used in
this study was based on the presence of neuroﬁbrillary
tangles and neuritic plaques in the hippocampal formation
and neocortical areas and met the criteria of the National
Institute on Aging (NIA) and the Consortium to establish a
registry for AD (CERAD) [35]. Hippocampal brain tissue
from ten AD cases and from seven age-matched control
subjects was evaluated for QC expression and for pE-Ab
deposition (Table 1). Anatomical subﬁelds and layers of
the human hippocampal formation at the level of 13, 23
and 31 mm were identiﬁed using Nissl-stained sections and
the atlas of the human brain [18, 30].
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Fifteen-millimeter-thick tissue blocks were prepared in the
frontal plane according to the atlas of the human brain [30]
and ﬁxed in 4% paraformaldehyde in 0.1 M phosphate-
buffered saline (PBS), pH 7.4 for 3–4 days. Areas con-
taining the regions of interest were cryoprotected in 30%
sucrose in 0.1 M PBS, pH 7.4. Series of 30-lm-thick
sections were cut on a freezing microtome and collected in
PBS containing 0.1% sodium azide.
Experimental animals
Inorder to relate QCexpression topE-Abformation, female
wild-type and APP transgenic Tg2576 mice at the postnatal
age of 10, 12, 14, 16, 18 and 23 months were used for this
study(N = 3–5peragegroup).Ascontrolforthespeciﬁcity
of the QC immunohistochemical labelling, QC knock-out
mice generated on the basis of classical homologous
recombination approach were included [25, 36]. Cre-medi-
ated excision of exons 5 and 6 was conﬁrmed by PCR and
RT-PCR.Theconstitutivedeletionoftheseexonsresultedin
an additional frame shift and thus in a complete loss of the
C-terminal part of the protein (not shown).
Preparation of mouse brains for immunohistochemistry
Mice were deeply anaesthetized with pentobarbital and
perfused transcardially with 50 ml 0.9% saline containing
0.1% heparin followed by perfusion with 80 ml 4% para-
formaldehyde in PBS (0.1 M; pH 7.4). The brains were
removed from the skull and postﬁxed by immersion in the
same ﬁxative overnight at 4C. After cryoprotection in
30% sucrose in 0.1 M PBS for 3 days, the brains were
snap-frozen in n-hexane at -68C and stored at -20C.
Coronal sections (30 lm) were cut on a sliding microtome
and collected in 0.1 M PBS.
QC and pE-Ab antibodies
Immunohistochemistry to detect QC in human brain was
performed using a commercially available mouse anti-
Table 1 Human hippocampal brain tissue used for QC and pE-Ab labellings
Case
#
PMD
(h)
Gender Age
(years)
Brain
weight
(g)
COD Braak
score
MMSE
(last
score)
CERAD
neuritic
plaque score
CERAD
criteria
NIA criteria
(likelihood
of dementia)
Control Co1 2.75 Male 81 1,290 Cardiac/respiratory
failure
I – 0 Not met Not met
Co2 2.75 Female 85 1,020 Pancreatic cancer II – 0 Not met Not met
Co3 1.0 Female 85 1,085 Abdominal lymphoma II – 0 Not met Not met
Co4 2.5 Female 86 1,145 Pulmonary ﬁbrosis III 27/30 0 Not met Not met
Co5 3.0 Female 89 1,200 Congestive heart
failure
III 30/30 A Not met Not met
Co6 2.75 Female 75 1,110 Pulmonary embolus III 29/30 0 Not met Not met
Co7 3.0 Male 82 1,240 Renal failure/COPD III 26/30 A Not met Not met
Mean 2.5 5/2 83.3 1,155
AD AD1 4.0 Female 82 932 Failure to thrive; AD VI – C Deﬁnite AD High
AD2 3.0 Female 82 925 Cardiac/respiratory
failure
VI – C Deﬁnite AD High
AD3 1.5 Female 85 850 Failure to thrive VI – C Deﬁnite AD High
AD4 1.5 Female 79 950 Cardiac/respiratory
failure; AD
VI – C Deﬁnite AD High
AD5 1.83 Female 84 1,080 End stage AD VI 00/30 C Deﬁnite AD High
AD6 1.5 Female 85 940 Breast cancer;
end stage AD
VI 02/30 C Deﬁnite AD High
AD7 2.25 Male 78 1,120 AD VI 07/30 C Deﬁnite AD High
AD8 3.16 Male 80 1,000 AD VI 01/30 C Deﬁnite AD High
AD9 3.5 Male 77 1,200 End stage AD VI 04/30 C Deﬁnite AD High
AD10 2.5 Male 87 1,100 End stage AD VI 13/30 C Deﬁnite AD High
Mean 2.5 6/4 81.9 1,010
AD Alzheimer’s disease, PMD post mortem delay, Co control, COD cause of death, MMSE Mini-Mental State Examination, CERAD Con-
sortium to Establish a Registry for Alzheimer’s Disease (0 none, A sparse, B moderate, C frequent), NIA National Institute on Aging
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123human QC antiserum (A01; Abnova; 1:500). Additionally,
the speciﬁcity of QC immunolabelling was validated by
similar staining patterns obtained employing the rabbit
anti-QC antiserum 1301 (1:500), which was raised against
recombinant full-length mouse QC expressed in yeast. This
antiserum has been characterized recently [25, 36] and was
shown to detect mouse, rat and human QC in Western blot
analysis and immunohistochemistry, which appears con-
ceivable considering a 85% protein sequence identity.
Moreover, the speciﬁcity of the QC antiserum was previ-
ously shown by the robust labelling of mouse hypothalamic
neurons, a known source of QC and of peptide hormones
modiﬁed by QC, and by the absence of this labelling in
brains from QC knock-out mice [25, 36].
pE-Ab peptides in brains of transgenic mice and of AD
patients were detected using the mouse monoclonal anti-
body mab2-48 (Synaptic Systems, Go ¨ttingen, Germany),
which has been thoroughly characterized by Wirths et al.
[60]. This antibody speciﬁcally detects the pE3-Ab neo-
epitope generated by QC activity and does not cross-react
with endogenous mouse Ab nor with human Ab1-40/42,
N-truncated human Ab3-40/42 lacking the pE modiﬁca-
tion, or pE11-Ab. When required for double-labelling
procedures a rabbit anti-pE-Ab antiserum (Synaptic Sys-
tems) was used. The rabbit anti-pE-Ab and mouse anti-pE-
Ab antibodies showed an identical staining pattern in
mouse and human brain tissue as revealed by double
immunoﬂuorescent labelling (not shown).
Immunohistochemical labellings
A detailed description of the single, double and triple
immunohistochemical labellings performed in human and
in Tg2576 mouse brain sections is given in the Supple-
mentary Information 1. Brieﬂy, speciﬁc primary antibodies
raised in different species and standard immunochemical
protocols were followed to reveal co-localization of pE-Ab
with QC and with total Ab peptide pools. The presence of
the respective antigens was visualized using chromogens
(DAB, DAB-Ni) and ﬂuorescent dyes (Cy2, Cy3, TOPRO-
3) as described in [25, 36].
Confocal laser scanning microscopy
Laser scanning microscopy (LSM 510, Zeiss, Oberkochen,
Germany) was performed to reveal co-localization of (1)
QC with pE-Ab and cellular nuclei or (2) pE-Ab with total
Ab pools. For Cy2-labelled antigens (green ﬂuorescence),
an argon laser with 488 nm excitation was used and
emission from Cy2 was recorded at 510 nm applying a
low-range band pass (505–550 nm). For Cy3-labelled
antigens (red ﬂuorescence), a helium–neon laser with
543 nm excitation was used and emission from Cy3 at
570 nm was detected applying high-range band pass
(560–615 nm). Nuclei labelled with TOPRO-3 were visu-
alized by excitation at 633 nm and detection of TOPRO-3
emission above a long pass of 655 nm.
Receptor autoradiography
Receptor autoradiography to detect adrenergic receptor
subtypes as a measure of noradrenergic hippocampal
innervation in rodent brain was carried out as described
previously [27]. Brieﬂy, 12-lm-thick brain slices cut in the
coronal plane were mounted onto gelatin-coated slides and
pre-incubated with 170 mM Tris–HCl (pH 7.4) at RT for
15 min to wash out endogenous ligand and to equilibrate
the brain tissue. For the detection of the a1-adrenoceptor,
brain sections were incubated in the same buffer containing
1n M [
3H]prazosine for 30 min at RT. The a2-adreno-
ceptor subtype was detected using [
3H]rauwolscine (5 nM)
as radioligand. As [
3H]rauwolscine does not discriminate
between a2-adrenoceptors and 5-HT1A receptors, 5-HT1A
receptors were masked with unlabelled serotonin (0.3 lM)
and the incubation was performed for 30 min at RT. The
presence of the b1/2-adrenoceptor was determined using
[
3H]dihydroalprenolol (3 nM) as radioligand for 1 h at RT.
After the respective incubation periods, sections were
washed twice in ice-cold buffer for 5 min, followed by a
short dipping into ice-cold distilled water. The labelled and
dried tissue sections were then apposed to tritium-sensitive
ﬁlm (
3H-Hyperﬁlm, Amersham) at 4C for 3–5 weeks. The
ﬁlms were developed with Kodak D19 developer for
5 min, ﬁxed, rinsed and dried. Optical density readings
from the autoradiographs obtained were recorded across
the hippocampus using the MCID image analysis program
(Imaging Research Inc., St. Catharines, Ontario, Canada),
corrected for background and displayed as thick proﬁles
from dorsal to ventral.
Cell culture and QC enzymatic activity assays
Next, we employed cell culture experiments to elucidate
whether QC protein accumulates intracellularly or whether
it is constitutively released into the culture medium by QC
expressing neurons. For this purpose, different neuronal
cell types were used, i.e. the QC expressing mouse hypo-
thalamic neuronal cell line GT1-7 [32], kindly provided by
I. Vorberg/H. Scha ¨tzl; Institute of Virology at Technical
University of Munich, and mouse primary neurons derived
from wild type and from QC knock-out foetuses of gesta-
tion day 16. Three days after seeding neurons in DMEM
containing 5% horse serum and 19 antibiotic mixture, the
medium was replaced by serum-free cultivation medium
and cultures were maintained for 1, 3 and 5 days in vitro
without change of medium. At the end of the cultivation
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were harvested, washed in PBS, centrifuged at 8009g for
8 min and stored at -20C pending QC activity measure-
ments. In another set of experiments, veratridine (Sigma;
50 lM) and potassium chloride (Sigma; 50 mM) were used
to pharmacologically stimulate vesicular release by neu-
ronal depolarization in 15 min pulse experiments.
QC activity was measured by a discontinuous HPLC-
method using the substrate H-Gln-bNA as described pre-
viously [13]. Brieﬂy, QC containing cell lysate or cell
culture supernatant was incubated with substrate H-Gln-
bNA. Test samples were taken and reaction was stopped by
boiling for 5 min. Analysis for pGlu-bNA formation was
done using RP18 LiChroCART HPLC Cartridge and the
HPLC-system D-7000 (Merck-Hitachi). QC activity was
quantiﬁed from a standard curve of pGlu-bNA under assay
conditions.
QC live cell imaging
In order to demonstrate transport of QC in neuronal pro-
cesses, live cell imaging was performed. Constructs
encoding QC fused to enhanced green ﬂuorescent protein
(QC-EGFP) were generated as described elsewhere [14].
The construct was conﬁrmed by sequencing and isolated
for cell culture purposes using EndoFree Plasmid Maxi Kit
(Qiagen). Transfection of GT1-7 cells differentiated by
serum deprivation for 72 h was performed by incubation
with 10 ll lipofectamine 2000 (Invitrogen) and 4 lg
plasmid DNA per well for 6 h. Twelve hours after trans-
fection, QC-EGFP was detected using a Zeiss Cell
Observer system equipped with an Axiocam MRC and a
639 objective lens. In control experiments, cells were
transfected with EGFP constructs lacking the QC cDNA.
Statistical analyses
Quantitative data on QC enzymatic activity given in Fig. 6
are mean values of ﬁve independent experiments ± SEM.
Data were analysed by one-way ANOVA, followed by post
hoc analysis (Newman–Keuls test).
Results
Ab deposit/plaque nomenclature
In this paper, we employ the terms ‘‘focal’’ and ‘‘diffuse’’
Ab deposits to distinguish between dense plaque mor-
phology containing a neuronal soma or remains thereof on
the one hand and more loosely aggregated pE-Ab without
apparent association with a neuronal cell body on the other.
In analogy to current classiﬁcations of Ab plaque
pathology (reviewed in [17]) the term focal deposit relates
to dense-cored [16], neuritic [8], and classic and compact
[2] plaques. Since we focused on the relationship between
QC expression and pE-Ab aggregation, the presence or
absence of dystrophic neurites was not included in the
plaque classiﬁcation.
pE-Ab deposition in AD hippocampus
In the human hippocampal formation from AD subjects,
pE-Ab deposits were detected in a structured, laminated
orientation as shown in Fig. 1a. In particular, pE-Ab
deposits were found lined-up in the dentate gyrus (DG)
molecular layer. Additionally, pE-Ab aggregates were
detected in stratum lacunosum moleculare and stratum
radiatum of the hippocampus proper but barely in granular
and pyramidal cell layers. The pattern of pE-Ab deposits
described above was found at different levels of the AD
hippocampal formation (Fig. 1b). In contrast, hippocampal
brain sections from control subjects were almost devoid of
pE-Ab deposits (Fig. 1b) and of plaques composed of
unmodiﬁed Ab peptides (not shown). Interestingly, pE-Ab
deposits present in the AD hippocampus differed signiﬁ-
cantly with respect to their morphology and to their
association with QC. Applying two different histological
double-labelling procedures depending on (1) peroxidase
as marker enzyme and (2) immunoﬂuorescent labellings, a
diffuse type of pE-Ab aggregates not associated with QC
immunoreactive neurons and a dense-core type of pE-Ab
deposits frequently associated with QC positive neurons
were identiﬁed (Fig. 1c).
Developmental proﬁle of pE-Ab aggregate formation
in Tg2576 mouse brain
To substantiate observations made in AD brain in an ani-
mal model of AD, the temporal and spatial appearance of
pE-Ab was studied in brains of APP transgenic Tg2576
mice at the age of postnatal month (PM) 10, 12, 14, 16, 18
and 23. pE-Ab immunoreactive deposits were already
detectable at PM 10 in entorhinal cortex. At later stages,
pE-Ab deposits also appeared in cingulate cortex (PM 12),
in the DG molecular layer (PM 14), in stratum lacunosum
moleculare and striatum (PM 16), in parietal cortex (PM
18) and more hippocampal and neocortical subﬁelds (PM
23) (Fig. 2). During the aging process, pE-Ab load in all
affected brain structures steadily increased.
Relation of QC expression to pE-Ab deposition
in Tg2576 hippocampus
In order to relate QC expression to pE-Ab generation by
individual neurons and to pE-Ab plaque formation, we
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As demonstrated in Fig. 3, most QC expressing interneu-
rons in the hippocampal formation were detected along the
stratum lacunosum moleculare of the hippocampus proper.
QC immunoreactive neurons were also present in the
polymorphic and at lower density in the molecular layer of
DG, as well as in strata radiatum and oriens of cornu am-
monis, but were largely absent from granular and
pyramidal cell layers (Fig. 3). These principal cell layers
did not show signiﬁcant numbers of pE-Ab deposits.
pE-Ab plaques were most abundantly formed in the DG
molecular layer just below the hippocampal ﬁssure, but to a
lesser extent in strata lacunosum moleculare and oriens
(Fig. 3). Thus, there is only a weak spatial correlation
betweenhighestnumbersofQCimmunoreactiveneuronson
the one hand and highest density of pE-Ab deposits on the
other in speciﬁc layers of the aged Tg2576 hippocampus.
Attempting to unveil the cause for this discrepancy, we
performed double immunoﬂuorescent labellings for QC
and pE-Ab and analysed the morphology of hippocampal
Fig. 1 pE-Ab deposition in human hippocampus. a In the human
hippocampal formation, pE-Ab deposits were detected in a structured,
laminated orientation as shown here at the transverse level of 23 mm.
The Nissl staining (top) visualizes the hippocampal lamination and
allows to spatialize pE-Ab deposits detected in consecutive brain
sections (middle). In particular, pE-Ab deposits were found lined-up
in the DG molecular layer. Additionally, pE-Ab aggregates were
detected in stratum lacunosum moleculare (slm) and stratum radiatum
(sr) of the hippocampus proper but barely in granular and pyramidal
cell layers. This localization is shown schematically in the bottom
image (bottom). The scale bar in the top microphotograph applies to
all images. b The pattern of pE-Ab deposits described in a can be also
found at other levels of the AD hippocampal formation as shown in 3
columns from left to right. In contrast, hippocampal brain sections
from control subjects (Co) appear devoid of pE-Ab deposits (right).
c Typical examples of pE-Ab plaque morphology and its relation to
QC. Both, DAB/DAB-Ni (top) and ﬂuorescent labellings (bottom)
reveal a diffuse type of pE-Ab aggregates not associated with QC-
immunoreactive neurons and a focal, more condensed type of pE-Ab
deposits frequently associated with QC-positive neuronal somata. The
scale bars in b and c apply to all images in one line. cc corpus
callosum, so stratum oriens, pyr pyramidal cell layer, sr stratum
radiatum, slm stratum lacunosum moleculare, DG dentate gyrus,
DGm molecular layer of dentate gyrus, DGpl polymorphic layer
(hilus) of dentate gyrus, DGg granular layer of dentate gyrus,
hs vestigial hippocampal sulcus, eCo entorhinal cortex, CA cornu
ammonis, PrS presubiculum, Sub subiculum
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the hippocampal stratum lacunosum moleculare, a layer
with numerous QC immunoreactive interneurons, we fre-
quently observed intraneuronal pE-Ab accumulation as
well as pE-Ab aggregates displaying the size and shape of
neurons (Fig. 4a). In many cases, QC immunoreactivity
and nuclear staining were also detected in these aggregates
suggesting that this type of pE-Ab aggregate may have
directly emanated from the somata of QC expressing
interneurons.
In contrast, the DG molecular layer contained relatively
few QC expressing interneurons, compared to an increas-
ingly high pE-Ab plaque load in aging transgenic animals.
Interestingly, pE-Ab deposits in the DG molecular layer
frequently exhibited a different morphology compared to
the dense type described above. These plaques appeared
more diffuse, lacked the neuron-like shape and displayed
neither QC immunoreactivity nor neuronal nuclei staining
in their center (Fig. 4b). We thus considered the possibility
of an alternative mechanism of QC-driven pE-Ab plaque
generation in the hippocampus in addition to pE-Ab
accumulation in the cell bodies of local QC synthesizing
interneurons. There are a number of reports demonstrating
that general Ab plaque deposition in the DG molecular
layer of APP transgenic mice is dependent on the intact
perforant and alvear pathways arising from the entorhinal
cortex [10, 28]. This is consistent with axonal transport of
Ab and its synaptic release [37]. In analogy, we considered
a mechanism in which QC and/or pE-Ab could be released
by afferents of projection neurons terminating in deﬁned
hippocampal subﬁelds such as the DG molecular layer. The
entorhinal cortex on its part expresses signiﬁcant amounts
of QC and is the ﬁrst brain region affected by pE-Ab
pathology in Tg2576 mice (see Fig. 2).
Composition of pE-Ab versus unmodiﬁed Ab
in plaques
Based on the unique aggregation velocity of pE-Ab pep-
tides compared to any other form of Ab peptides, a
function of pE-modiﬁed Ab peptides as seed for aggrega-
tion and co-aggregation of unmodiﬁed Ab has been
postulated. If this hypothesis was true, pE-Ab should be
localized in the center of such aggregates, coated by
unmodiﬁed Ab. To address this issue, double immunoﬂu-
orescent labellings of Ab with pE-Ab-speciﬁc and general
Ab antibodies (4G8) were performed. As shown for the
Tg2576 hippocampus in Fig. 5,p E - A b was always detec-
ted in the center of morphologically different types of Ab
aggregates and covered by non-pE-Ab peptides. Similar
observations were made for human brain tissue (not
shown). It is important to note that antibody 4G8, when
Fig. 2 Developmental proﬁle
of pE-Ab formation in Tg2576
mouse brain. pE-Ab
immunoreactive deposits were
detected from PM 10 onwards.
At this age, pE-Ab deposits
were only present in the
entorhinal cortex. The brain
structure affected at the next
postnatal age analysed was
cingulate cortex (PM 12),
followed by DG molecular layer
(PM 14), stratum lacunosum
moleculare and striatum (PM
16), parietal cortex (PM 18) and
more hippocampal and
neocortical subﬁelds (PM 23).
In each brain region affected by
pE-Ab pathology, there was an
increase in the pE-Ab load at
older ages
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123applied at low dilution, also recognizes full-length APP and
longer APP fragments harbouring the 4G8 epitope. How-
ever, at the high dilution used here (1:5,000), the antibody
then detects only Ab [11].
A role of noradrenergic hippocampal innervation
for diffuse pE-Ab plaque formation?
In order to obtain evidence for a contribution of QC
expressed by distant projection neurons in the formation of
diffuse hippocampal pE-Ab plaques, three alternative
approaches were employed. Firstly, we visualized norad-
renergic receptors in the hippocampal formation by
receptor autoradiography as a measure of noradrenergic
innervation. Autoradiographs revealed signiﬁcant and
lamina-speciﬁc expression of a1, a2 and b1/2 noradren-
ergic receptor subtypes in particular in the DG molecular
layer and the stratum lacunosum moleculare (Fig. 6a),
indicating a substantial noradrenergic innervation of the
layers harbouring diffuse pE-Ab deposits. In contrast,
pyramidal and granular cell layers, which do not exhibit
diffuse pE-Ab aggregates, displayed—if any—only a low
density of these noradrenergic receptor subtypes. Secondly,
we quantiﬁed intracellular versus secreted QC in mouse
hypothalamic GT1-7 neurons and in primary neurons over
deﬁned cultivation periods. After 24 h of cultivation, QC
activity in conditioned media was 10-times higher than
intracellular QC activity (Fig. 6b). Moreover, we observed
stable intracellular QC activity but a 2.5-fold increase in
QC activity in the cultivation medium over a period of
5 days (Fig. 6b), consistent with QC being constitutively
secreted from neuronal cells. Additionally, the secretion of
enzymatically active QC was reduced in a gene dosage-
dependent manner in primary neuronal cultures from QC
knock-out mice (Fig. 6b). Finally, neuronal depolarization
by application of a high extracellular K
? concentration
(50 mM) or by veratridine treatment (50 lM) in 15 min
pulse experiments resulted in a modest stimulation of QC
secretion by 24 and 53%, respectively.
Thirdly, live cell imaging of QC-EGFP-transfected
GT1-7 cells demonstrated fast transport of QC in neuronal
processes (Fig. 6c). Together, these data demonstrate that
QC is transported in neurites and is for the most part
constitutively secreted from neuronal cells. In addition, QC
was released in a regulated manner, after stimulation with
KCl or veratridine. Therefore, it appears reasonable to
conclude that the enzyme exerts its enzymatic activity in
vivo in target areas distant from the somata of QC-
expressing neurons.
Fig. 3 Spatial relation of QC and pE-Ab. Immunohistochemistry for
QC (top) revealed a low number of QC-positive neurons in the DG
molecular layer (DGm) below the hippocampal ﬁssure (hf, dotted red
line), in stratum oriens (so) and in the polymorphic layer of DG
(DGpl). The highest number of QC immunoreactive neurons was
detected in the stratum lacunosum moleculare (slm) of the hippo-
campus proper, above the hippocampal ﬁssure. Along this
hippocampal layer and in stratum oriens (so) early pE-pathology
was already observed in 16-month-old Tg2576 mice, matching the
presence of QC neurons (middle). However, the highest density of pE-
Ab deposits was detected in the molecular layer of the DG (below the
hippocampal ﬁssure), which only contained few QC immunoreactive
neurons. Bottom a schematic representation of the localization and
density of QC immunoreactive neurons (green triangles) and pE-Ab
deposits (red circles) in mouse hippocampus is shown. cc corpus
callosum, so stratum oriens, pyr pyramidal cell layer, sr stratum
radiatum, slm stratum lacunosum moleculare, DGm molecular layer
of dentate gyrus, DGpl polymorphic layer (hilus) of dentate gyrus,
DGg granular layer of dentate gyrus, hf hippocampal ﬁssure
c
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The aim of this study was to reveal the spatial relation of
QC-expressing neurons with pE-Ab aggregates in brain.
For a number of reasons, the hippocampus was used as a
model system to address that question: (1) it is structured
in deﬁned layers that are (2) characterized by the pres-
ence of high versus low numbers of QC immunoreactive
Fig. 4 Lamina-speciﬁc
appearance of focal and diffuse
pE-Ab deposits. a QC and pE-
Ab co-occur at sites of QC
immunoreactive interneurons.
In the stratum lacunosum
moleculare of the hippocampus,
pE-Ab aggregates often
appeared in neuron-like
structures. In the DAB labelling
(top) pE-Ab was often present
intraneuronally or forming a
neuron-like rim. Double
immunoﬂuorescent labellings
frequently revealed co-
occurrence of pE-Ab (red) with
its anabolic enzyme QC (green).
The bottom left ﬁgure shows an
example of a QC-expressing
neuron with intraneuronal pE-
Ab labelling. The cellular origin
of QC and pE-Ab is
demonstrated by the co-
labelling of the nucleus (blue).
In the bottom right ﬁgure an
example of a disrupted QC-
labelled neuron is shown. In that
case, pE-Ab appeared as a
neuronal rim-like structure and
contained defragmented nuclear
material. b Hippocampal pE-Ab
deposits in a Tg2576
hippocampal layer with few QC
neurons. In the DG molecular
layer of the hippocampal
formation—which only contains
few QC immunoreactive
neurons—there was a
signiﬁcant number of diffuse
pE-Ab plaques (top), which
differed morphologically from
those arising from QC
immunoreactive interneurons of
the stratum lacunosum
moleculare. These diffuse
plaques were not associated
with QC immunoreactive
somata (bottom left and bottom
right) and were detected in
target ﬁelds that receive input
from projection neurons of the
ipsilateral entorhinal cortex and
locus coeruleus
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123interneurons in mice, (3) it is affected by pE-Ab pathol-
ogy and (4) it receives afferents from projection neurons
of the entorhinal cortex and locus coeruleus, which were
shown to robustly express QC in mouse and human brain
[36]. Moreover, hippocampal neurons are involved in the
realization of higher cognitive function such as spatial
orientation, learning and memory formation as well as in
the processing of emotion and stress (reviewed in [4, 19])
and are affected by both, tau and Ab pathology, at early
stages of AD [8]. Thus, dysfunction or degeneration of
hippocampal neurons has been shown to contribute to
cognitive decline in AD patients [22, 46, 58]. Although
the cellular and molecular mechanisms contributing to
hippocampal pathology and neurodegeneration are not
well established, there is recent solid evidence that the
pE-modiﬁcation of N-truncated Ab peptides contributes to
the formation of neurotoxic high molecular weight Ab
aggregates [1, 26, 42, 59]. This modiﬁcation is catalyzed
by QC at an acidic pH optimum present at intracellular
sites of Ab generation [14, 47]. However, thorough his-
topathological evidence for a role of QC in pE-Ab
generation has still been lacking and, therefore, was
addressed in this study.
In the human hippocampal formation from AD patients
we observed a strikingly laminated appearance of pE-Ab
deposits in the DG molecular layer and a marked pE-Ab
pathology in stratum lacunosum moleculare of CA1, CA2
and CA3 subﬁelds as well as in the subiculum. We detected
a similar pattern of Ab deposition using antibodies against
full-length Ab peptides in our brain material. This is con-
sistent with the previously demonstrated layer-speciﬁc Ab
deposition in AD hippocampus [7, 12]. Interestingly, two
types of pE-Ab deposits were identiﬁed: cored/focal pE-Ab
aggregates, frequently associated with QC-immunoreactive
neurons or neuronal debris and more diffuse pE-Ab
deposits not associated with QC neurons. Both types of
plaques were found to be composed of pE-Ab and of their
unmodiﬁed counterparts with pE-Ab being present in the
center and full-length Ab in the periphery of the deposits.
We did not observe pE-Ab immunonegative plaques. In the
present study six out of seven control subjects were devoid
of hippocampal pE-Ab plaque pathology. One non-
Fig. 5 pE-Ab forms the core of
Ab deposits. pE-Ab (left, green)
is localized in the center of Ab
deposits in mouse hippocampus
as shown by the double
labelling with the antibody 4G8
(middle, red), which recognizes
amino acids 17–24 of Ab
peptides and, therefore, all
N- and C-terminally truncated/
modiﬁed variants including pE-
Ab as indicated by yellow
colour in the overlay channel
(right)
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123demented control subject displayed moderate pE-Ab pla-
que immunoreactivity in the hippocampus.
In order to further assess the role of QC in the formation
of distinct types of pE-Ab deposits, brains of APP trans-
genic mice were analysed. Similar to the pathology in the
brains from AD patients, pE-Ab aggregates in brains of
Tg2576 mice were ﬁrst detected in the entorhinal cortex,
around PM 10. This indicates that all prerequisites for pE-
Ab generation such as transgenic human APP expression,
as well as b- and c-secretase activity, N-terminal Ab
truncation and QC activity are present and active in en-
torhinal cortex neurons. The density of pE-Ab aggregates
steadily increased in entorhinal cortex and additional
neocortical structures were subsequently affected by pE-
Ab pathology during the aging process of Tg2576 mice.
In the Tg2576 hippocampal formation, pE-Ab deposits
were ﬁrst detected around PM 14 in the DG molecular
layer. Additionally, starting at PM 16, there was formation
of pE-Ab aggregates at sites of QC immunoreactive somata
in the stratum lacunosum moleculare of the hippocampus
proper. In many cases, these latter pE-Ab aggregates dis-
played a neuron-like shape, were co-localized with QC and
contained a cellular nucleus in the center. Thus, we con-
clude that pE-Ab peptides in the stratum lacunosum
moleculare might be generated intracellularly and accu-
mulate in the somata of local QC-expressing interneurons.
At later stages these intracellular aggregates may eventu-
ally become detrimental to the cell leading to the nuclear
and somatic ‘‘crater-like’’ disintegration of QC/pE-Ab-co-
expressing neurons in this hippocampal subregion. In
contrast, pE-Ab deposits in the DG molecular layer, which
only sparsely contains QC immunoreactive interneurons
[25], frequently lacked this neuron-like shape, did not
display a central nucleus and had a diffuse structure. These
observations are consistent with those made in AD hip-
pocampus raising the question about the role of QC and the
cellular and molecular mechanisms contributing to diffuse
pE-Ab deposition in the DG molecular layer.
Interestingly, this hippocampal layer receives afferent
input from QC-rich entorhinal cortex neurons that are
affected early by pE-Ab pathology, via the perforant and
alvear pathways. In particular, layer II entorhinal cortex
neurons innervate the DG molecular layer, and neurons of
layer III project to the stratum lacunosum moleculare of
cornu ammonis [57, 61], the very hippocampal layers along
which pE-Ab plaques are formed most consistently. This
structural connectivity opens the possibility of an addi-
tional independent plaque-inducing mechanism, namely
hippocampal pE-Ab seeding via axonal transport processes
and synaptic release from terminals of entorhinal cortex
projection neurons. Indeed, axonal transport of APP and
Ab-containing fragments via the perforant path [10] and
deposition of Ab in terminal zones of the entorhinal-
dentate projection in APP transgenic mice [54] have
already been described. Compelling evidence for a causa-
tive role of perforant path afferents in the development of
hippocampal Ab plaque pathology, however, derives from
a number of lesion studies. Both, ablation of the entorhinal
cortex as well as transection of the perforant path result in
signiﬁcantly decreased amyloid burden in the hippocampus
of APP transgenic mice [28, 53]. Importantly, entorhinal
cortex lesions in APP/PS1-transgenic mice solely lead to a
marked reduction in the number of diffuse but not of focal
Ab deposits in the deafferented dentate gyrus [56] also
suggesting different plaque-inducing mechanisms. Addi-
tionally, selective overexpression of human mutant APP in
mouse entorhinal cortex layer II/III neurons resulted in
behavioural abnormalities characteristic for widespread
neuronal APP overexpression, and in deﬁcits in hippo-
campus-dependent spatial learning and memory [24].
The occurrence of two distinct types of neuron-related
Ab deposits, diffuse and focal plaques, is also a well-
known feature of the human brain parenchyma affected by
AD as reviewed by Duyckaerts et al. [17]. Here, we
demonstrate an analogous pattern of the formation of dif-
fuse and dense core pE-Ab containing plaques in mouse
and human brain affected by Ab pathology. We conclude
that QC, the enzyme catalyzing the pE-modiﬁcation of Ab,
may contribute to the formation of morphologically distinct
types of pE-Ab plaques via different mechanisms. These
include local pE-Ab generation at sites of QC-expressing
hippocampal interneurons and QC and/or pE-Ab transport
from entorhinal cortex projection neurons and layer-spe-
ciﬁc synaptic release at hippocampal terminal zones.
However, we would like to stress that diffuse pE-Ab
aggregates detected in this study may not be exclusively
present in the extracellular space, but could also be local-
ized within neurites of QC-rich neurons arising from
entorhinal cortex or hippocampal subﬁelds.
A similar mechanism contributing to laminar hippo-
campal pE-Ab plaque pathology may apply to subcortical
neuronal projections. Thorough anatomical investigations
have demonstrated that the hippocampus receives wide-
spread and layer-speciﬁc noradrenergic input from the
locus coeruleus [5, 29]. This neuronal population has
recently been shown to express high amounts of QC in
mouse and human brain and to display signiﬁcant pE-Ab
pathology in AD [36]. Thus, diffuse pE-Ab plaques
observed in the Tg2576 stratum lacunosum moleculare of
the hippocampus proper may also result from secretion of
pE-Ab generated by locus coeruleus neurons.
Alternatively, QC itself may be anterogradly transported
and released in target regions of projection neurons, and
then modify extracellularly deposited N-truncated Ab
peptides. Indeed, there is solid cell physiological evidence
to support this notion. For example, QC was found to be
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123localized along the secretory pathway; i.e. endoplasmic
reticulum, trans-Golgi network and secretory granules in
mouse brain neurons [25]. Moreover, the QC live imaging
and enzymatic activity data presented here indicate a
constitutive secretion of QC from neurons under basal
physiological conditions. Thus, the high QC levels of en-
torhinal cortex and noradrenergic locus coeruleus neurons,
their substantial projections to the DG molecular layer and
stratum lacunosum moleculare of the hippocampus proper
and the secretion of QC from cultured neurons are sup-
portive for a role of secreted pE-Ab and/or QC in the
generation of diffuse pE-Ab deposits. Such a ‘‘seeding
from the distance’’ of Ab plaques by brainstem locus
coeruleus neurons has already been discussed to contribute
to the development of AD pathology [37]. Furthermore, in
an APP transgenic mouse model, the seeding of Ab
deposits in brain structures lacking transgene expression
has been shown via synaptic Ab release from projection
neurons [11]. These data are also consistent with an animal
experimental study in which embryonic foetal cells were
grafted into the brains of APP23 mice. The authors
observed diffusion of soluble Ab in the extracellular space
and concluded that this process is involved in the spread of
Ab pathology and in neurodegeneration [33]. Also, the
thorough analysis of brains from AD patients and from
non-demented controls suggests deﬁned phases of Ab
formation and the expansion of the pathology from
neocortical to allocortical brain regions, followed by
diencephalic, brainstem and cerebellar Ab deposition [55].
Considering the sublayer-speciﬁc plaque formation in
Tg2576 mouse hippocampus it has to be noted, however,
that the DG polymorphic layer barely develops pE-Ab
pathology. While the absence of diffuse pE-Ab deposits is
consistent with the lack of entorhinal projection terminals
and noradrenergic receptors, the absence of dense core pE-
Ab plaque pathology in spite of the presence of QC-
expressing interneurons in this area was unexpected.
However, pE-Ab formation in Tg2576 mice does not only
require QC activity, but also human APP expression, its
processing by b- and c-secretases and, ﬁnally, N-terminal
truncation to generate the QC substrate. Therefore, the
absence of one or more factors indispensable for pE-Ab
formation may explain this phenomenon.
Our observations on the central localization of pE-Ab
peptides within Ab plaques match biochemical data sug-
gesting that pE-Ab peptides act as seed for aggregation and
co-aggregation of non-modiﬁed Ab peptides [15, 31, 51].
In all morphologically distinct types of Ab aggregates
investigated here, pE-Ab was always detected in the core
of the deposited material. Taken together, we describe two
morphologically distinct types of pE-Ab aggregates in the
hippocampus of AD patients and of Tg2576 mice, which
can be spatially related to local QC-expressing interneu-
rons and to target ﬁelds of QC-rich projection neurons
arising in entorhinal cortex and/or locus coeruleus,
respectively. These data provide histopathological evi-
dence for QC being a prerequisite for pE-Ab pathology in
vivo and further underline the therapeutic potential of QC
inhibition in AD.
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Fig. 6 Noradrenergic input to hippocampal layers and secretion of
QC from cultured neurons. a The noradrenergic input to the
hippocampal formation was visualized by the lamina-speciﬁc detec-
tion of a1, a2 and b1/2 noradrenergic receptor subtypes using
receptor autoradiography. Note the dense labelling for b1/2 adreno-
ceptors in the DG molecular layer and for a2 adrenoceptors in the DG
molecular layer and in the strata lacunosum moleculare and radiatum
of cornu ammonis. b QC enzymatic activity in conditioned medium
(open bars) of cultured mouse primary neurons (top left) and of
hypothalamic GT1-7 cells (top right) is signiﬁcantly higher than
intraneuronal QC activity (black bars). Additionally, in both cell
types intraneuronal QC activity was rather stable during a cultivation
period of 5 days, whereas QC activity in the conditioned medium
increased steadily, consistent with its constitutive secretion. More-
over, in the conditioned medium from QC knock-out mouse neurons
cultured for 24 h, the enzymatic QC activity was reduced in a gene
dose-dependent manner (bottom left). Depolarization of GT1-7 cells
by 50 mM KCl or 50 lM veratridine treatment for 15 min resulted in
a modest increase in QC secretion by 24 and 53%, respectively
(bottom right). Statistically signiﬁcant by one-way ANOVA, followed
by post-hoc analysis (Newman–Keuls test) at *p\0.05 and
***p\0.001 compared to day 1 or respective control sample.
c Live cell imaging of GT1-7 neurons expressing QC-EGFP. GT1-7
cells were differentiated by serum deprivation for 72 h and then
transfected with QC-EGFP constructs. Twelve hours after transfection
GT1-7 cells expressing the QC-EGFP fusion protein were identiﬁed
by EGFP ﬂuorescence (top). Three images per second were taken and
representative examples are shown in 10-s intervals to demonstrate
fast transport of QC-EGFP (botttom, red and blue circles)
b
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